AU2023269792A1 - Multispecific binding molecule proproteins and uses thereof - Google Patents

Multispecific binding molecule proproteins and uses thereof Download PDF

Info

Publication number
AU2023269792A1
AU2023269792A1 AU2023269792A AU2023269792A AU2023269792A1 AU 2023269792 A1 AU2023269792 A1 AU 2023269792A1 AU 2023269792 A AU2023269792 A AU 2023269792A AU 2023269792 A AU2023269792 A AU 2023269792A AU 2023269792 A1 AU2023269792 A1 AU 2023269792A1
Authority
AU
Australia
Prior art keywords
abs
domain
binding molecule
mbm
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023269792A
Other languages
English (en)
Inventor
Alison CRAWFORD
Lauric Haber
Chia-Yang Lin
Eric Smith
Tong Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of AU2023269792A1 publication Critical patent/AU2023269792A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2023269792A 2022-05-11 2023-05-10 Multispecific binding molecule proproteins and uses thereof Pending AU2023269792A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263340891P 2022-05-11 2022-05-11
US63/340,891 2022-05-11
US202363481291P 2023-01-24 2023-01-24
US63/481,291 2023-01-24
US202363489812P 2023-03-13 2023-03-13
US63/489,812 2023-03-13
PCT/US2023/066841 WO2023220647A1 (en) 2022-05-11 2023-05-10 Multispecific binding molecule proproteins and uses thereof

Publications (1)

Publication Number Publication Date
AU2023269792A1 true AU2023269792A1 (en) 2024-11-28

Family

ID=86760424

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023269792A Pending AU2023269792A1 (en) 2022-05-11 2023-05-10 Multispecific binding molecule proproteins and uses thereof

Country Status (9)

Country Link
US (1) US20250340668A1 (enExample)
EP (1) EP4522649A1 (enExample)
JP (1) JP2025516596A (enExample)
KR (1) KR20250024872A (enExample)
CN (1) CN119546628A (enExample)
AU (1) AU2023269792A1 (enExample)
CA (1) CA3252786A1 (enExample)
IL (1) IL316892A (enExample)
WO (1) WO2023220647A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025007062A1 (en) * 2023-06-30 2025-01-02 The Regents Of The University Of California Pro-polypeptides and methods of using and designing the same
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof
WO2025199278A2 (en) * 2024-03-20 2025-09-25 Regeneron Pharmaceuticals, Inc. Masked multispecific antigen-binding molecules with cleavable linkers

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
CA2128511C (en) 1992-01-23 2006-11-07 Andreas Pluckthun Monomeric and dimeric antibody-fragment fusion proteins
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
GB9720054D0 (en) 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
PT1644412E (pt) 2003-07-01 2015-12-23 Ucb Biopharma Sprl Fragmentos de anticorpos fab modificados
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
JP5985481B2 (ja) 2010-09-01 2016-09-06 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 抗イディオタイプ抗体の迅速な産生
MX385344B (es) 2012-11-28 2025-03-18 Zymeworks Bc Inc Pares de cadena pesada-cadena ligera de inmunoglobulina modificados genéticamente y usos de estos.
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
US10047167B2 (en) 2013-03-15 2018-08-14 Eli Lilly And Company Methods for producing fabs and bi-specific antibodies
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
DK3277725T3 (da) 2015-03-30 2021-01-11 Regeneron Pharma Konstante tungkædeområder med reduceret binding til FC-gammareceptorer
PL3368572T5 (pl) 2015-10-02 2026-07-20 Les Laboratoires Servier Przeciwciała anty-PD-1 oraz kompozycje
PL3964529T3 (pl) 2016-01-22 2025-10-27 MabQuest SA Nieblokujące przeciwciała specyficzne względem pd1
WO2017162587A1 (en) 2016-03-22 2017-09-28 F. Hoffmann-La Roche Ag Protease-activated t cell bispecific molecules
US11390676B2 (en) 2016-10-13 2022-07-19 Symphogen A/S Anti-LAG-3 antibodies and compositions

Also Published As

Publication number Publication date
CA3252786A1 (en) 2023-11-16
CN119546628A (zh) 2025-02-28
WO2023220647A1 (en) 2023-11-16
US20250340668A1 (en) 2025-11-06
KR20250024872A (ko) 2025-02-19
JP2025516596A (ja) 2025-05-30
IL316892A (en) 2025-01-01
EP4522649A1 (en) 2025-03-19

Similar Documents

Publication Publication Date Title
US20250066441A1 (en) Il12 receptor agonists and methods of use thereof
EP4522649A1 (en) Multispecific binding molecule proproteins and uses thereof
AU2023325402A1 (en) Interferon receptor agonists and uses thereof
AU2023325400A1 (en) Interferon proproteins and uses thereof
WO2023235848A1 (en) Interleukin-2 proproteins and uses thereof
JP2025525885A (ja) Ｇｕｃｙ２ｃとｃｄ３に特異的に結合する抗原結合分子及びその医薬的使用
AU2023276766A1 (en) Interleukin-2 proproteins and uses thereof
HK40116914A (en) Multispecific binding molecule proproteins and uses thereof
HK40121930A (en) Interleukin-2 proproteins and uses thereof
HK40123893A (en) Interleukin-2 proproteins and uses thereof
HK40126891A (en) Interferon proproteins and uses thereof
WO2025106469A1 (en) Engineered heavy chain variable domains and uses thereof
HK40126890A (en) Interferon receptor agonists and uses thereof
WO2025199243A1 (en) Trivalent multispecific binding molecules and methods of use thereof
WO2026076013A1 (en) Tumor-targeted il2 receptor agonists and multispecific t-cell engagers